Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

397 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group.
Sjöström J, Blomqvist C, Mouridsen H, Pluzanska A, Ottosson-Lönn S, Bengtsson NO, Ostenstad B, Mjaaland I, Palm-Sjövall M, Wist E, Valvere V, Anderson H, Bergh J. Sjöström J, et al. Among authors: mouridsen h. Eur J Cancer. 1999 Aug;35(8):1194-201. doi: 10.1016/s0959-8049(99)00122-7. Eur J Cancer. 1999. PMID: 10615229 Clinical Trial.
Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian breast group.
Hakamies-Blomqvist L, Luoma M, Sjöström J, Pluzanska A, Sjödin M, Mouridsen H, Ostenstad B, Mjaaland I, Ottosson-Lönn S, Bergh J, Malmström P, Blomqvist C. Hakamies-Blomqvist L, et al. Among authors: mouridsen h. Eur J Cancer. 2000 Jul;36(11):1411-7. doi: 10.1016/s0959-8049(00)00126-x. Eur J Cancer. 2000. PMID: 10899655 Clinical Trial.
Timing of quality of life (QoL) assessments as a source of error in oncological trials.
Hakamies-Blomqvist L, Luoma ML, Sjöström J, Pluzanska A, Sjödin M, Mouridsen H, Østenstad B, Mjaaland I, Ottosson S, Bergh J, Malmström PO, Blomqvist C. Hakamies-Blomqvist L, et al. Among authors: mouridsen h. J Adv Nurs. 2001 Sep;35(5):709-16. doi: 10.1046/j.1365-2648.2001.01903.x. J Adv Nurs. 2001. PMID: 11529973
Phase II study of tauromustine in disseminated malignant melanoma.
Nolte H, Gjedde SB, Lindegaard-Madsen E, Bergh J, Blomquist E, Mouridsen HT. Nolte H, et al. Among authors: mouridsen ht. Eur J Cancer Clin Oncol. 1989 Apr;25(4):655-7. doi: 10.1016/0277-5379(89)90201-0. Eur J Cancer Clin Oncol. 1989. PMID: 2714342
Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line endocrine treatment in advanced breast cancer: an EORTC phase III study (10863).
Beex L, Rose C, Mouridsen H, Jassem J, Nooij M, Estape J, Paridaens R, Piccart M, Gorlia T, Lardenoije S, Baila L. Beex L, et al. Among authors: mouridsen h. Eur J Cancer. 2006 Dec;42(18):3178-85. doi: 10.1016/j.ejca.2006.08.020. Epub 2006 Oct 12. Eur J Cancer. 2006. PMID: 17045796 Clinical Trial.
Phase II study of tauromustine in disseminated malignant melanoma.
Gjedde SB, Mouridsen HT, L-Madsen E, Jensen NV, Blomquist E, Bergh J, Söderberg M, Wählby S. Gjedde SB, et al. Among authors: mouridsen ht. Eur J Cancer. 1994;30A(4):566. doi: 10.1016/0959-8049(94)90448-0. Eur J Cancer. 1994. PMID: 8018421 Clinical Trial. No abstract available.
Tamoxifen in high-risk premenopausal women with primary breast cancer receiving adjuvant chemotherapy. Report from the Danish Breast Cancer co-operative Group DBCG 82B Trial.
Andersson M, Kamby C, Jensen MB, Mouridsen H, Ejlertsen B, Dombernowsky P, Rose C, Cold S, Overgaard M, Andersen J, Kjaer M. Andersson M, et al. Among authors: mouridsen h. Eur J Cancer. 1999 Nov;35(12):1659-66. doi: 10.1016/s0959-8049(99)00141-0. Eur J Cancer. 1999. PMID: 10674010 Clinical Trial.
397 results